WeVote
Log In

Bill

Bill

SB 401

PHARMACEUTICALS: Provides for a Prescription Drug Affordability Board. (8/1/26)

2026 Regular Session Introduced by Tehmi Chassion and 1 co-sponsor

Creates Louisiana Prescription Drug Affordability Board to cap drug prices; raises federal preemption and market access concerns while aiming to reduce medication costs.

Effective date: See Act.
0
WeVote Research Nonpartisan
Bill Summary · SB 401

Legislative bill overview

SB 401 establishes a Prescription Drug Affordability Board in Louisiana empowered to set maximum allowable prices for prescription drugs sold within the state. The board would have regulatory authority to cap what pharmaceutical manufacturers and distributors can charge for medications, effective August 1, 2026.

Why is this important

Prescription drug costs significantly impact healthcare affordability for Louisiana residents, and this bill attempts to address that by giving the state direct price-setting authority. However, this approach directly challenges federal pharmaceutical pricing frameworks and could trigger legal challenges or affect drug availability in the state.

Potential points of contention

  • Federal preemption concerns: The federal government regulates drug pricing through FDA and Medicare. States have limited authority to unilaterally set drug prices, and this bill may violate the Commerce Clause or conflict with federal law.
  • Market access and supply: Manufacturers may refuse to sell in Louisiana if prices are set below profitability thresholds, potentially reducing drug availability rather than improving affordability.
  • Board composition and expertise: The bill's effectiveness depends heavily on how the board is structured, staffed, and whether it has adequate expertise in pharmacology, economics, and healthcare systems to set appropriate prices without distorting markets.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.